U.S. Beverage Stock News

NasdaqGS:CGON
NasdaqGS:CGONBiotechs

CG Oncology (CGON) Is Up 6.8% After Naming Biotech Veteran Jim DeTore CFO - Has The Bull Case Changed?

On April 13, 2026, CG Oncology, Inc. appointed Jim DeTore as Chief Financial Officer after he had served as Interim Principal Financial and Accounting Officer since November 2025 and previously held senior finance roles at several biotechnology companies, including Neurogastrx, Proteostasis Therapeutics, and Bluebird Bio. This appointment adds long-tenured biotech financial leadership at a time when CG Oncology’s oncolytic immunotherapy program for bladder cancer is attracting increased...
NYSE:CIEN
NYSE:CIENCommunications

Ciena’s Subsea Deal With Lightstorm Meets Soaring Valuation And AI Hopes

Ciena (NYSE:CIEN) is partnering with Lightstorm to upgrade the Japan, Guam, Australia submarine cable system with advanced optical networking technology. The project focuses on the Tokyo to Sydney route, where capacity is set to be quadrupled to support heavier data traffic. The upgraded system is intended to serve cloud and AI workloads that rely on high performance international connectivity. Ciena comes into this agreement with Lightstorm after a period of very strong share price...
NasdaqGM:CRML
NasdaqGM:CRMLMetals and Mining

Is Critical Metals (CRML) Using Its US$60 Million Private Placement To De‑Risk Growth Or Dilute Value?

Critical Metals Corp. recently entered into a securities purchase agreement to issue 5,999,998 ordinary shares at US$10.00 each, raising US$59,999,980 through a Regulation D private placement that was expected to close on or about April 22, 2026. This sizeable capital injection via a private placement can influence how investors think about Critical Metals’ funding capacity, project pipeline, and future dilution risk. We’ll now examine how this nearly US$60 million private placement shapes...
NasdaqGM:SFST
NasdaqGM:SFSTBanks

Southern First Bancshares (SFST) 91.5% Earnings Growth Reinforces Bullish Narratives Despite Valuation Concerns

Southern First Bancshares (SFST) opened Q1 2026 with total revenue of US$32.5 million and basic EPS of US$1.21, while trailing 12 month revenue sat at US$121.9 million and EPS at US$4.31 off net income of US$35.0 million. Over the past few quarters, revenue has moved from US$25.7 million in Q1 2025 to US$31.2 million in Q4 2025 and US$32.5 million in Q1 2026. Quarterly EPS over the same stretch has run from US$0.65 to US$1.23 and now US$1.21, highlighting higher earnings, a 28.7% trailing net...
NYSE:TSM
NYSE:TSMSemiconductor

Assessing Taiwan Semiconductor Manufacturing’s Valuation After Strong Recent Share Price Momentum

TSMC’s recent performance in focus Taiwan Semiconductor Manufacturing (NYSE:TSM) has been drawing attention after an 11.8% monthly return and a 12.9% gain over the past 3 months, prompting investors to reassess its recent share performance. See our latest analysis for Taiwan Semiconductor Manufacturing. At a share price of $368.08, the stock has a 30 day share price return of 11.8% and a year to date share price return of 15.2%, while the 1 year total shareholder return is 145.5%, suggesting...
NYSE:PR
NYSE:PROil and Gas

Should Goldman’s 2026 Marketing Praise and Gas Realization Focus Require Action From Permian Resources (PR) Investors?

Earlier in April 2026, Goldman Sachs issued a constructive outlook on Permian Resources ahead of earnings, citing the company’s pure-play Delaware Basin focus, execution record, and emphasis on incremental capital and cost efficiencies. The bank also highlighted Permian Resources’ plans to expand marketing efforts in 2026 to improve natural gas realizations despite ongoing Waha pricing pressure, underscoring management’s attention to pricing quality rather than just production volumes. We’ll...
NasdaqGS:BRZE
NasdaqGS:BRZESoftware

Why Braze (BRZE) Is Up 15.6% After Beating Revenue And EBITDA Expectations And What's Next

Braze recently reported quarterly results showing 27.9% year-on-year revenue growth, beating analyst expectations on both billings and EBITDA for the period. This outperformance against consensus forecasts highlights how Braze’s execution and customer engagement platform traction are influencing current expectations for the business. We’ll now examine how this stronger-than-expected revenue and EBITDA performance may influence Braze’s existing investment narrative and future...
NYSE:UBER
NYSE:UBERTransportation

Uber Cybersecurity Award Adds Context To Undervalued NYSE UBER Thesis

Uber Technologies (NYSE:UBER) received a major CSO Award in 2026 for its work in Human Risk Management. The company was recognized for using signal driven data to shape security behaviors across its global workforce. The award highlights Uber's focus on cybersecurity for both users and employees. For a company like Uber, which runs global ride hailing and delivery platforms, digital security sits close to the core of the business model. Large, distributed workforces and high volumes of data...
NasdaqGS:SHOP
NasdaqGS:SHOPIT

Is It Too Late To Consider Shopify (SHOP) After Recent Share Price Rebound?

Wondering if Shopify at around US$131 per share still offers value or if most of the upside is already priced in? This article focuses squarely on what the current market price might be implying. The stock has returned 2.9% over the last week and 8.3% over the last month, while year to date it is down 16.6% and up 44.2% over the last year, with a 3 year return of 182.8% and 5 year return of 1.7%. Recent coverage has focused on Shopify's role as a major e commerce platform and its position in...
NasdaqGS:IDYA
NasdaqGS:IDYABiotechs

IDEAYA And AstraZeneca Collaboration Adds New Dimension To IDE849 And Valuation

IDEAYA Biosciences (NasdaqGS:IDYA) has entered a clinical collaboration with AstraZeneca to study IDE849, a DLL3 TOP1 antibody drug conjugate. The program will evaluate IDE849 in combination with Imfinzi in extensive stage small cell lung cancer and other DLL3 upregulated tumors. For readers tracking IDEAYA mainly through its uveal melanoma drug darovasertib, this collaboration with AstraZeneca broadens the story. The company, trading at $31.83, has delivered a 70.9% return over the past...
NYSE:SWK
NYSE:SWKMachinery

Stanley Black & Decker CEO Shift Puts Cost Targets In Focus

Stanley Black & Decker (NYSE:SWK) announced that Donald Allan will step down as CEO and become Executive Chair. Chris Nelson is set to assume the CEO role effective October 1. Management outlined progress on a multi year transformation, including a roadmap targeting US$2b in cost reductions. The company is aiming for 35% adjusted gross margins while managing macroeconomic and tariff related pressures. Stanley Black & Decker, a major global manufacturer of tools, outdoor equipment, and...
NasdaqGS:WTFC
NasdaqGS:WTFCBanks

Wintrust Financial (WTFC) Margin Strength And EPS Growth Reinforce Bullish Narratives In Q1 2026

Wintrust Financial (WTFC) opened 2026 with Q1 revenue of US$682.4 million and basic EPS of US$3.26, while trailing twelve month revenue stood at US$2.7 billion and EPS at US$12.10. This gives investors a clear snapshot of both the latest quarter and the broader earnings run rate. Over the past year, revenue has moved from US$2.3 billion to US$2.7 billion and trailing EPS has shifted from US$10.47 to US$12.10, setting the backdrop for how the market may read this earnings print. With a...
NYSE:VZ
NYSE:VZTelecom

Is It Time To Reassess Verizon (VZ) After Recent Share Price Swings?

If you are wondering whether Verizon Communications at around US$46.27 offers enough value for the risks involved, this article breaks down what the current price might imply. The stock is up 1.7% over the last 7 days and 14.3% over the past year, while the 30 day return is a 7.4% decline. The 3 year return stands at 51.8% and the 5 year return at 12.0%. Recent coverage has focused on Verizon Communications as a core US telecom player, with attention on its network investments, competitive...
NYSE:HUBB
NYSE:HUBBElectrical

Is It Too Late To Consider Hubbell (HUBB) After A Strong Multi Year Share Price Run?

Wondering if Hubbell's share price still offers value after a strong run, or if most of the opportunity is already reflected in the current US$549.11 level. Hubbell has posted returns of 0.6% over the last 7 days, 15.4% over the past month, 18.6% year to date, 63.3% over 1 year, 120.3% over 3 years and 206.6% over 5 years, which naturally raises questions about how the current price stacks up against fundamentals. These moves sit against a backdrop of ongoing interest in companies involved...
NYSE:CALX
NYSE:CALXCommunications

Is It Time To Reconsider Calix (CALX) After A 31.8% One Year Return?

If you are wondering whether Calix at around US$49.58 still offers value or is starting to look stretched, the key is to look closely at what you are paying for each dollar of its future potential. The share price performance is mixed, with a 1.6% gain over the last 7 days, a 1.5% decline over 30 days, a 7.5% decline year to date, and a 31.8% return over the past year. These shifts can change how the market views both risk and opportunity. Investors have been reacting to ongoing industry...
NasdaqGS:MNST
NasdaqGS:MNSTBeverage

The Tactical Trio Blueprint For Solid Balance Sheet And Fundamentals

With inflation, energy shocks and bond yields all in focus, many investors are looking for companies that are not only surviving the noise but also backed by strong fundamentals. A solid balance sheet and high return on equity can help show which businesses are using capital efficiently while keeping financial risk in check. That is exactly what the Solid Balance Sheet and Fundamentals screener is built to highlight. In this article, you will see three stocks filtered by that approach, along...
NasdaqGS:NUVL
NasdaqGS:NUVLBiotechs

A Look At Nuvalent (NUVL) Valuation As Zidesamtinib NDA Acceptance Advances Late Stage Pipeline

Nuvalent (NUVL) is back in focus after the FDA accepted its New Drug Application for zidesamtinib in ROS1-positive NSCLC and set a Prescription Drug User Fee Act action date for September 18, 2026. See our latest analysis for Nuvalent. The FDA’s NDA acceptance and upcoming data presentations arrive after a 30-day share price return of 13.04% and a year-to-date share price return of 6.24%, while the 1-year total shareholder return of 50.06% and 3-year total shareholder return above 3x suggest...
NYSE:VRT
NYSE:VRTElectrical

Vertiv Extends Data Center Role Into Grid Services As Stock Soars

Vertiv Holdings Co (NYSE:VRT) and CPower Energy have agreed to work together to use data center battery energy storage systems as grid resources. The collaboration is aimed at providing resilience and grid services in constrained power markets, using existing data center infrastructure. The move extends Vertiv's role in data centers into grid integration and demand response, reflecting growing focus on energy flexibility and sustainability. Vertiv, trading on the NYSE as VRT, currently has...
NasdaqGS:PRGS
NasdaqGS:PRGSSoftware

A Look At Progress Software (PRGS) Valuation As Bengaluru AI Expansion Gains Ground

Progress Software (PRGS) shares are in focus after the company announced a relocation and expansion of its Bengaluru office, highlighting India’s growing role in its AI work and customer facing operations. See our latest analysis for Progress Software. The Bengaluru expansion comes at a time when Progress Software’s share price return has weakened, with a 29.6% decline over 90 days and a 46.9% drop in 1 year total shareholder return. This is despite a 6.7% 7 day share price rebound that hints...
NasdaqGS:KTOS
NasdaqGS:KTOSAerospace & Defense

Is Kratos Defense & Security Solutions (KTOS) Still Attractive After Its Recent Pullback?

If you are wondering whether Kratos Defense & Security Solutions at US$68.55 still offers value after a strong run, it helps to step back and look at what the current price might already be assuming. The stock has given up 6.9% over the past week and 19.0% over the past month, yet it still sits on a 113.4% return over the last year and a very large gain over three years, with a 153.0% return over five years. Recent market attention around defense and security spending has kept companies like...
NYSE:MLI
NYSE:MLIMachinery

Mueller Industries (MLI) Margin Expansion Reinforces Bullish Narratives Ahead Of Q1 2026 Earnings

Mueller Industries (MLI) opened Q1 2026 with revenue of US$1.2b and basic EPS of US$2.19, supported by net income of US$239.0m. This sets a clear marker for how the year is starting to shape up. Over the past year, the company has seen trailing twelve month revenue move from US$3.8b to US$4.4b, with basic EPS over that period rising from US$5.43 to US$7.76. This gives investors a fuller picture of the earnings engine behind the latest quarterly print. With a trailing net margin sitting...
NYSE:DHR
NYSE:DHRLife Sciences

Danaher (DHR) Margin Decline Challenges Bullish Earnings Growth Narrative In Q1 2026

Q1 2026 earnings snapshot Danaher (DHR) opened 2026 with Q1 revenue of US$5.9b and basic EPS of US$1.45, setting the tone for how investors will judge the rest of the year against a share price around US$194.54. Over the past six reported quarters, revenue has ranged from US$5.7b to US$6.8b while quarterly basic EPS has moved between roughly US$0.77 and US$1.67, giving you a clear view of how top line scale and per share earnings have tracked together into the latest print. With trailing 12...
OTCPK:BLHK
OTCPK:BLHKBanks

Blueharbor Bank (OTCPK:BLHK) Net Margin Expansion Reinforces Bullish Earnings Narrative

blueharbor bank (OTCPK:BLHK) has opened Q1 2026 with total revenue of US$6.7 million and basic EPS of US$1.12, with the trailing twelve months showing revenue of US$24.7 million and basic EPS of US$4.05 as a backdrop. Over the past year, revenue has moved from US$18.8 million to US$24.7 million on a trailing basis, while basic EPS has shifted from US$2.31 to US$4.05, giving you a clear view of the recent earnings trajectory behind this quarter’s results. With a trailing net profit margin of...
NasdaqGS:INTU
NasdaqGS:INTUSoftware

Is It Time To Reconsider Intuit (INTU) After Recent Software Sector Sentiment Shift?

Wondering whether Intuit at around US$404.85 is starting to look attractively priced, or if the recent share moves are just noise in your watchlist? Over the past week the stock has moved 10.4%, set against a 30 day return of an 11.1% decline and a year to date return of a 35.7% decline, which puts the 1 year return at a 30.1% decline and the 3 and 5 year returns close to flat. Recent headlines have focused on Intuit's role as a key software provider and on how market sentiment around large...